Rallybio Corp. RLYB 深 沪
等待开盘 07-21 09:30:00 美东时间
0.43
-0.025
-5.43%
华盛通- 最 高0.4661
- 今 开0.4548
- 成交量 76.70万股
- 最 低 0.43
- 昨 收 0.4547
- 总市值 1789.40万
- 52周最高 1.54
- 市盈率 静 --
- 换手率 1.84%
- 52周最低 0.2201
- 委 比 -4.71%
- 总股本 4161.40万
- 历史最高 25.78
- 量 比 0.72
- 振 幅 7.94%
- 历史最低 0.2201
- 每 手 1
- 风险率 0.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments.
07-08 21:44
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement
Rallybio stock soared on Tuesday after the company reached an agreement with Re...
07-08 21:12
Recursion Acquires Rallybio's Full Interest In Joint ENPP1 Inhibitor Program And Associated Backup Molecule For Treatment Of Hypophosphatasia; Rallybio To Receive $7.5M Upfront, With Potential For $17.5M More In Preclinical And Clinical Milestones
Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor
07-08 20:04
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Ironwood Pharmaceuticals (NASDAQ:IRWD) stock rose 15.2% to $0.71 durin...
06-14 05:05
Rallybio Initiates Dosing In Phase 1 Confirmatory PK/PD Study Evaluating RLYB116, Subcutaneously Injected C5 Inhibitor
– Potential to Address a Broad Range of Complement-Mediated Diseases with Initial Focus on Immune Platelet Transfusion Refractoriness and Refractory Antiphospholipid Syndrome –– Data Readouts Expected from Cohort 1 in 3Q
06-12 20:16
Rallybio Q1 EPS $(0.21) Beats $(0.26) Estimate, Sales $212.00K
Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.26) by 19.23 percent. This is a 55.32 percent increase over losses of $(0.47) per share from the same
05-08 20:20
Jones Trading Downgrades Rallybio to Hold
Jones Trading analyst Catherine Novack downgrades Rallybio (NASDAQ:RLYB) from Buy to Hold.
04-15 19:54
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints
Rallybio ends RLYB212 trial for FNAIT; shifts focus to RLYB116 and preclinical assets with 2025 trial milestones and $6 billion market potential.
04-09 01:01
JMP Securities downgrades Rallybio (RLYB) to a Hold
Rallybio (RLYB – Research Report) received a Hold rating and price target from ...
04-08 23:45
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Virpax Pharmaceuticals (NASDAQ:VRPX) shares moved upwards by 28.9% to ...
03-19 05:05
